Skip Page Header

Home > UK Clinical guidelines for use of depot buprenorphine (Buvidal®) in the treatment of opioid dependence.

Halliday, Kate, ed. Lintzeris, Nicholas and Dunlop, Adrian and Finch, Emily and Parsons, Graham and Hard, Bernadette and Brinksman, Steve (2020) UK Clinical guidelines for use of depot buprenorphine (Buvidal®) in the treatment of opioid dependence. London: SMMGP.

[img]
Preview
PDF (UK Clinical guidelines for use of depot buprenorphine)
992kB

This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.

Buvidal® is a prolonged-release formulation of buprenorphine (BPN), registered in the UK for ‘Treatment of opioid dependence within a framework of medical, social and psychological treatment’. Treatment is intended for use in adults and adolescents aged 16 years or over. Buvidal® is designed to be administered by subcutaneous injection once a week or once a month.


Repository Staff Only: item control page